

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the announcements of GenScript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 4 April 2019 and 13 January 2021.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on 1 February 2021 (New York time), Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, announced that the Committee for Medicinal Products for Human Use (the “**CHMP**”) of the European Medicines Agency (the “**EMA**”) has accepted a request for an accelerated assessment of the Marketing Authorisation Application (the “**MAA**”) for the investigational B-cell maturation antigen (BCMA) targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel).

The request was made by Legend Biotech’s collaborator, Janssen Biotech, Inc. (“**Janssen**”). An accelerated assessment of the MAA is granted by the CHMP when a medicinal product is expected to be of major public health interest and therapeutic innovation.

The MAA, which is targeted for submission in the first half of 2021, is based on results from the pivotal Phase 1b/2 CARTITUDE-1 study which evaluated the efficacy and safety of cilta-cel in the treatment of patients with relapsed and/or refractory multiple myeloma. Results from the study were presented (Abstract #177) at the 62nd American Society of Hematology Annual Meeting in December 2020. For details, please see refer to the announcement of the Company dated 6 December 2020.

The Company believes that the acceptance of the request for an accelerated assessment is an important testament for the potential use of cilta-cel in treating patients with multiple myeloma. Together with Legend Biotech’s collaborator, Janssen, the Group looks forward to working with the EMA as the Group advances this treatment option toward market and provides new hope for patients.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 1 February 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*